Survey Explores Use of Radium Drug Xofigo in Prostate Cancer Patients
Nearly one-quarter of oncologists are prescribers 1 month after launch (September 16)
BioTrends Research Group, a research and advisory firm located in Exton, Penn., finds that, at 1 month post-launch of Xofigo (radium RA 223 dichloride, Algeta/Bayer HealthCare) in the U.S., approximately one-quarter of surveyed U.S. medical oncologists indicated that they have prescribed the drug. Moreover, nearly half of current nonprescribers stated that they would prescribe Xofigo in the next 4 to 6 months.
Notably, most of the current nonprescribers indicated that they would prescribe Xofigo to both their docetaxel-naive and docetaxel-pretreated patients with metastatic castrate-resistant prostate cancer (mCRPC).
The new report also finds that more than half of surveyed medical oncologists reported high favorability toward Xofigo, and most respondents indicated a high level of interest in the drug. For docetaxel-naive mCRPC, the highest proportion of surveyed medical oncologists indicated that the bone-targeted mechanism of action of Xofigo and its safety profile are among the agent’s main advantages. For docetaxel-pretreated mCRPC, the main perceived advantages of Xofigo over Zytiga (abiraterone acetate, Johnson & Johnson/Janssen Biotech) and Xtandi (enzalutamide, Medivation/Astellas Pharma) lie in Xofigo’s limited and fixed treatment duration and in the fact that it is an efficacious bone-targeted agent, according to surveyed medical oncologists.
“Surveyed medical oncologists cited the need to refer patients to a licensed nuclear medicine facility as one of the main disadvantages of Xofigo compared to other agents used to treat docetaxel-naive and docetaxel-pretreated mCRPC,” said analyst Khurram Nawaz, MSc. “We also find that just over half of Xofigo non-prescribers indicated that they are aware of the nearest location licensed for Xofigo administration.”
Source: BioTrends Research Group; September 16, 2013.